Business Wire (Fri, 17-Jul 7:30 AM ET)
Market Chameleon (Wed, 15-Jul 4:33 AM ET)
Business Wire (Wed, 15-Jul 7:00 AM ET)
Business Wire (Tue, 14-Jul 6:54 PM ET)
Achieve Life Sciences Appoints Jeffrey Farrow and Reid Waldman, MD to Board of Directors
Globe Newswire (Tue, 2-Jun 8:30 AM ET)
Veradermics to Present at Upcoming June Investor Conferences
Business Wire (Thu, 28-May 4:30 PM ET)
Business Wire (Wed, 27-May 7:30 AM ET)
Veradermics Announces Two Poster Presentations on VDPHL01 at the 2026 Music City SCALE Symposium
Business Wire (Thu, 14-May 7:30 AM ET)
Business Wire (Tue, 12-May 7:30 AM ET)
Market Chameleon (Mon, 27-Apr 6:29 AM ET)
Veradermics Inc clinical-stage biopharmaceutical company focused on developing therapeutics to address pervasive treatment challenges in prevalent aesthetic and dermatological conditions. The company operates in a single segment of allocating resources, assessing performance, and making operating decisions.
Veradermics trades on the NYSE stock market under the symbol MANE.
As of August 3, 2026, MANE stock price declined to $101.53 with 548,890 million shares trading.
MANE has a beta of -0.63, meaning it tends to be less sensitive to market movements. MANE has a correlation of 0.01 to the broad based SPY ETF.
MANE has a market cap of $4.24 billion. This is considered a Mid Cap stock.
The top ETF exchange traded funds that MANE belongs to (by Net Assets): VTI, IWM, VXF, VTWO, IWO.
MANE support price is $98.83 and resistance is $111.17 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MANE shares will trade within this expected range on the day.
